Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Cerebral deposition of the beta-amyloid peptide (A beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A beta (ref. 1) and the subsequent cloning of its precursor protein, no direct evidence for the actual production of discrete A beta has been reported. Here we investigate whether A beta is present in human biological fluids using antibodies specific for an epitope within A beta that spans the site of normal constitutive cleavage. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A beta and a novel A beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies that shed light on the physiological role of Aβ in non-diseased brains show that Aβ plays a role in synaptic transmission and is involved in learning and memory formation [18–22].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [18]
In the citing paper
“Recently, we and others have shown that normal processing of the large amyloid f3 protein precursor ({3-APP) secretes 4-kDa A(3 that is readily detected in human cerebrospinal fluid and in medium conditioned by cultured cells (3)(4)(5)(6).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [3]
In the citing paper
“The demonstration that A-related peptides with the same N terminals as the CTFs documented here are present in conditioned medium of cultured cells (Seubert et al., 1992;Naslund et al., 1994;Simons et al., 1996;Wang et al., 1996;Xu et al., 1998)”
From Alzheimer Amyloid Protein Precursor in the Rat Hippocampus: Transport and Processing through the Perforant Path (1998) · cites this paper as Seubert et al., 1992
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,410
Self-citationMutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,381
Self-citationChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,096
Cited by
Items 301–400 of 1,726
Interactions between APP secretases and inflammatory mediators
Sastre, M., Walter, J., & Gentleman, S. M. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-25 · Cited by 171
“(page number not for citation purposes) culture cell lines [4-6], suggesting that it is produced and secreted constitutively.”
BackgroundA metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor
Miyazaki, K., Hasegawa, M., Funahashi, K., & Umeda, M. (1993) · Nature · doi:10.1038/362839a0 · Cited by 175
Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Evin, G., & Weidemann, A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00063-3 · Cited by 170
A novel pathway for amyloid precursor protein processing
Portelius, E., Price, E., Brinkmalm, G., Stiteler, M., Olsson, M., Persson, R., Westman-Brinkmalm, A., Zetterberg, H., Simon, A. J., & Blennow, K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.06.002 · Cited by 168
Matsuzaki, K. (2014) · Accounts of Chemical Research · doi:10.1021/ar500127z · Cited by 170
Lee, J. P., Stimson, E. R., Ghilardi, J. R., Mantyh, P. W., Lu, Y.-A., Felix, A. M., Llanos, W., Behbin, A., Cummings, M., Van Criekinge, M., et al. (1995) · Biochemistry · doi:10.1021/bi00015a033 · Cited by 170
Brain Parenchymal and Microvascular Amyloid in Alzheimer's Disease
Vinters, H. V., Wang, Z. Z., & Secor, D. L. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00799.x · Cited by 171
(1994) · PubMed Central · Cited by 169
The sour side of neurodegenerative disorders: the effects of protein glycation
Miranda, H. V., & Outeiro, T. F. (2010) · The Journal of Pathology · doi:10.1002/path.2682 · Cited by 169
“are present in extracellular fluids [104,179–182].”
Kuo, Y.-M., Kokjohn, T. A., Watson, M. D., Woods, A. S., Cotter, R. J., Sue, L. I., Kalback, W. M., Emmerling, M. R., Beach, T. G., & Roher, A. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64947-4 · Cited by 167
Distribution of Cystine/Glutamate Exchange Transporter, System xc−, in the Mouse Brain
Sato, H., Tamba, M., Okuno, S., Sato, K., Keino-Masu, K., Masu, M., & Bannai, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-08028.2002 · Cited by 169
The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide
Storey, & Cappai (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00164.x · Cited by 169
Giovannelli, L., Casamenti, F., Scali, C., Bartolini, L., & Pepeu, G. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00610-h · Cited by 167
The Amyloid β Peptide (Aβ1-40) Is Thermodynamically Soluble at Physiological Concentrations
Sengupta, P., Garai, K., Sahoo, B., Shi, Y., Callaway, D. J. E., & Maiti, S. (2003) · Biochemistry · doi:10.1021/bi0341410 · Cited by 167
Das, S., & Potter, H. (1995) · Neuron · doi:10.1016/0896-6273(95)90300-3 · Cited by 167
MATTSON, M. P. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44401.x · Cited by 166
Apolipoprotein E and cholesterol in aging and disease in the brain
de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164
Human Serum Albumin Can Regulate Amyloid-β Peptide Fiber Growth in the Brain Interstitium
Stanyon, H. F., & Viles, J. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.360800 · Cited by 162
“5 nM concentrations (2), similar to A levels found in the cerebrospinal fluid (CSF) (3), A amyloid deposits are largely found in the interstitium within the brain.”
BackgroundSipe, J. D., & Cohen, A. S. (1994) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369409084679 · Cited by 165
Hong, W., Wang, Z., Liu, W., O’Malley, T. T., Jin, M., Willem, M., Haass, C., Frosch, M. P., & Walsh, D. M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1846-7 · Cited by 163
Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Estrada, L., & Soto, C. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318262 · Cited by 162
Peric, A., & Annaert, W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1379-7 · Cited by 161
LaFerla, F. M., Troncoso, J. C., Strickland, D. K., Kawas, C. H., & Jay, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119536 · Cited by 163
Amyloid-β Peptide Disruption of Lipid Membranes and the Effect of Metal Ions
Lau, T.-L., Ambroggio, E. E., Tew, D. J., Cappai, R., Masters, C. L., Fidelio, G. D., Barnham, K. J., & Separovic, F. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.091 · Cited by 160
?-Amyloid formation by myocytes of leptomeningeal vessels
Wisniewski, H. M., & Wegiel, J. (1994) · Acta Neuropathologica · doi:10.1007/bf00296738 · Cited by 162
“Recent studies show that ~-amyloid is a normal secretory product of cells that express [3PP [8, 19, 42 , 43].”
BackgroundTurner, R. S., Suzuki, N., Chyung, A. S. C., Younkin, S. G., & Lee, V. M.-Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8966 · Cited by 161
Intramembrane proteolysis by presenilins
Steiner, H., & Haass, C. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043065 · Cited by 161
Sandbrink, R., Masters, C. L., & Beyreuther, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42286-1 · Cited by 162
Ekinci, F. J., Malik, K. U., & Shea, T. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30322 · Cited by 163
Biological markers of amyloid β-related mechanisms in Alzheimer's disease
Hampel, H., Shen, Y., Walsh, D. M., Aisen, P., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.024 · Cited by 160
“Large soluble APP (sAPP) fragments are present in CSF (Seubert et al., 1992); however, the results from studies on CSF levels of total, α-or β-cleaved sAPP in AD have been contradictory, ranging from an increase (Lewczuk et al., in press), to no significant change (Hock et al., 1998; Olsson et al.,…”
BackgroundGrimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 159
“Since the major produced Aβ species end at position 40 or 42 (Haass et al., 1992; Seubert et al., 1992; Roher et al., 1993; Iwatsubo et al., 1994), one can assume that AICD should begin at position 41 or 43 (aa numbers referring to the Aβ sequence).”
BackgroundDuan, L., Bhattacharyya, B. J., Belmadani, A., Pan, L., Miller, R. J., & Kessler, J. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-3 · Cited by 159
“Aβ40 is normally the major form of secreted Aβ peptide recovered from cerebrospinal fluid, while Aβ42 represents less than 10% [6].”
BackgroundHawkes, C., & Kar, S. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.11.002 · Cited by 161
Klafki, H.-W., Abramowski, D., Swoboda, R., Paganetti, P. A., & Staufenbiel, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28655 · Cited by 159
Characterization of High-Affinity Binding between Gangliosides and Amyloid β-Protein
Ariga, T., Kobayashi, K., Hasegawa, A., Kiso, M., Ishida, H., & Miyatake, T. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2304 · Cited by 158
Metal Ion-dependent Effects of Clioquinol on the Fibril Growth of an Amyloid β Peptide
Raman, B., Ban, T., Yamaguchi, K.-I., Sakai, M., Kawai, T., Naiki, H., & Goto, Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500309200 · Cited by 159
Expression of Scavenger Receptors in Glial Cells
Alarcón, R., Fuenzalida, C., Santibáñez, M., & von Bernhardi, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414686200 · Cited by 158
Guénette, S. Y., Chen, J., Jondro, P. D., & Tanzi, R. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10832 · Cited by 158
Amyloidogenicity of rodent and human βA4 sequences
Dyrks, T., Dyrks, E., L. Masters, C., & Beyreuther, K. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81399-k · Cited by 160
Lord, A., Gumucio, A., Englund, H., Sehlin, D., Sundquist, V. S., Söderberg, L., Möller, C., Gellerfors, P., Lannfelt, L., Pettersson, F. E., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.08.007 · Cited by 158
Low-Density Lipoprotein Receptor Family
Bu, G., Li, Y., & Cam, J. (2001) · Molecular Neurobiology · doi:10.1385/mn:23:1:53 · Cited by 137
“Although Aβ is generated as a normal product of cellular metabolism (62), substantial data indicate that progressive accumulation of Aβ plays a central role in AD pathogenesis (63).”
BackgroundMurphy, M. P., Hickman, L. J., Eckman, C. B., Uljon, S. N., Wang, R., & Golde, T. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11914 · Cited by 157
LeBlanc, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-12-07837.1995 · Cited by 157
Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Czech, C., Tremp, G., & Pradier, L. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00033-7 · Cited by 158
Nepovimova, E., Uliassi, E., Korabecny, J., Peña-Altamira, L. E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010804 · Cited by 151
Wang, Z., Jackson, R. J., Hong, W., Taylor, W. M., Corbett, G. T., Moreno, A., Liu, W., Li, S., Frosch, M. P., Slutsky, I., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2009-17.2017 · Cited by 158
Tomiyama, T., Asano, S., Furiya, Y., Shirasawa, T., Endo, N., & Mori, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34045-0 · Cited by 154
Amyloid β protein in plasma from patients with sporadic Alzheimer's disease
Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., & Shoji, S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00143-8 · Cited by 156
Dementia of the eye: the role of amyloid beta in retinal degeneration
Ratnayaka, J. A., Serpell, L. C., & Lotery, A. J. (2015) · Eye · doi:10.1038/eye.2015.100 · Cited by 153
Nontoxic Amyloid β Peptide1-42 Suppresses Acetylcholine Synthesis
Hoshi, M., Takashima, A., Murayama, M., Yasutake, K., Yoshida, N., Ishiguro, K., Hoshino, T., & Imahori, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2038 · Cited by 150
Reaume, A. G., Howland, D. S., Trusko, S. P., Savage, M. J., Lang, D. M., Greenberg, B. D., Siman, R., & Scott, R. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23380 · Cited by 150
Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure
Soto, C., Castaño, E. M., Asok Kumar, R., Beavis, R. C., & Frangione, B. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12089-m · Cited by 150
Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149
“(sA/3) that is present in the circulation and CSF (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992; Vigo-Pelfrey et al., 1993) and is secreted by several different types of cells (Busciglio et al.”
BackgroundHomocysteine: a biomarker in neurodegenerative diseases
Herrmann, W., & Obeid, R. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.084 · Cited by 167
Baker, H. F., Ridley, R. M., Duchen, L. W., Crow, T. J., & Bruton, C. J. (1994) · Molecular Neurobiology · doi:10.1007/bf02778005 · Cited by 163
Solution Structure of Residues 1-28 of the Amyloid .beta.-Peptide
Talafous, J., Marcinowski, K. J., Klopman, G., & Zagorski, M. G. (1994) · Biochemistry · doi:10.1021/bi00191a006 · Cited by 178
Paik, S. R., Lee, J.-H., Kim, D.-H., Chang, C.-S., & Kim, J. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0207 · Cited by 148
Kanekiyo, T., Ban, T., Aritake, K., Huang, Z.-L., Qu, W.-M., Okazaki, I., Mohri, I., Murayama, S., Ozono, K., Taniike, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701585104 · Cited by 147
Long Amyloid .beta.-Protein Secreted from Wild-Type Human Neuroblastoma IMR-32 Cells
Asami-Odaka, A., Ishibashi, Y., Kikuchi, T., Kitada, C., & Suzuki, N. (1995) · Biochemistry · doi:10.1021/bi00032a022 · Cited by 149
Lanz, T. A., Himes, C. S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., & Merchant, K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048280 · Cited by 159
“…extracellular fluid, including the cerebrospinal fluid (CSF) and plasma of AD patients as part of the constitutive APP metabolism (Ida et al., 1996; Seubert et al., 1992), we set out to test the hypothesis that A levels in these clinically accessible fluids may provide a biomarker of -secretase…”
BackgroundPortelius, E., Tran, A. J., Andreasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., Blennow, K., & Westman-Brinkmalm, A. (2007) · Journal of Proteome Research · doi:10.1021/pr0703627 · Cited by 151
THE GENETICS AND MOLECULAR PATHOLOGY OF ALZHEIMER'S DISEASE
Selkoe, D. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70232-2 · Cited by 162
Self-citationChi, E. Y., Ege, C., Winans, A., Majewski, J. P., Wu, G., Kjær, K., & Lee, K. Y. C. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21887 · Cited by 150
Higaki, J., Quon, D., Zhong, Z., & Cordell, B. (1995) · Neuron · doi:10.1016/0896-6273(95)90322-4 · Cited by 122
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Malherbe, P., Richards, J. G., Gaillard, H., Thompson, A., Diener, C., Schuler, A., & Huber, G. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00174-6 · Cited by 156
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 156
Vieira, S. I., Rebelo, S., Esselmann, H., Wiltfang, J., Lah, J., Lane, R., Small, S. A., Gandy, S., da Cruz e Silva, E. F., & da Cruz e Silva, O. A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-40 · Cited by 132
“This peptide is generated by two consecutive proteolytic cleavages of its precursor, the Alzheimer’s amyloid precursor protein (APP), and is constitutively produced and secreted at low levels during APP trafficking [6,7].”
BackgroundMačkić, J. B., Bading, J. R., Ghiso, J. A., Walker, L. C., Wısnıewskı, T., Frangione, B., & Zloković, B. V. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00198-2 · Cited by 158
Selective ectodomain phosphorylation and regulated cleavage of beta‐amyloid precursor protein.
Hung, A. Y., & Selkoe, D. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06291.x · Cited by 178
Self-citationLee, M.-C., Yu, W.-C., Shih, Y.-H., Chen, C.-Y., Guo, Z.-H., Huang, S.-J., Chan, J. C. C., & Chen, Y.-R. (2018) · Scientific Reports · doi:10.1038/s41598-018-23122-x · Cited by 134
Self-citationJohnston, J. A., Cowburn, R. F., Norgren, S., Wiehager, B., Venizelos, N., Winblad, B., Vigo-Pelfrey, C., Schenk, D., Lannfelt, L., & O'Neill, C. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01137-0 · Cited by 115
Self-citationGursky, O., & Aleshkov, S. B. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00228-9 · Cited by 160
Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
Tamaoka, A., Sawamura, N., Fukushima, T., Shoji, S., Matsubara, E., Shoji, M., Hirai, S., Furiya, Y., Endoh, R., & Mori, H. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00314-0 · Cited by 157
Olsson, A., Csajbok, L. Z., �st, M., H�glund, K., Nyl�n, K., Rosengren, L., Nellg�rd, B., & Blennow, K. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0451-y · Cited by 150
“In addition to the Aβ production, which also occurs in normal subjects [33], the sub sequential β- and γ-secretase cleavage of APP also leads to a simultaneous release of soluble β-secretase cleaved APP (β-sAPP).”
BackgroundZloković, B. V. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00310-4 · Cited by 152
Aleshkov, S., Abraham, C. R., & Zannis, V. I. (1997) · Biochemistry · doi:10.1021/bi9626362 · Cited by 138
Kienlen-Campard, P., Tasiaux, B., Van Hees, J., Li, M., Huysseune, S., Sato, T., Fei, J. Z., Aimoto, S., Courtoy, P. J., Smith, S. O., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707142200 · Cited by 142
Accelerated A Deposition in APPswe/PS1 E9 Mice with Hemizygous Deletions of TTR (Transthyretin)
Choi, S. H., Leight, S. N., Lee, V. M.-Y., Li, T., Wong, P. C., Johnson, J. A., Saraiva, M. J., & Sisodia, S. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1919-07.2007 · Cited by 140
“Although this latter notion is attractive, it is important to note that TTR is not the only protein that binds A in CSF.”
BackgroundInfluentialPinnix, I., Musunuru, U., Tun, H., Sridharan, A., Golde, T., Eckman, C., Ziani-Cherif, C., Onstead, L., & Sambamurti, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005968200 · Cited by 140
Inhibition of β‐Amyloid Production by Activation of Protein Kinase C
Gabuzda, D., Busciglio, J., & Yankner, B. A. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb07479.x · Cited by 141
Biochemistry and Molecular Biology of Amyloid β‐Protein and the Mechanism of Alzheimer's Disease
(2008) · Handbook of Clinical Neurology · doi:10.1016/s0072-9752(07)01223-7 · Cited by 137
Self-citationTwenty years of Alzheimer’s disease‐causing mutations
Goate, A., & Hardy, J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07575.x · Cited by 137
“Predictions 1–3 have been largely borne out (Citron et al. 1992; Haass et al. 1992; Mullan et al. 1992; Seubert et al. 1992; Cai et al. 1993; Suzuki et al. 1994; Scheuner et al. 1996), and the identification of presenilins as the other genes involved in the Mendelian disorder (St George-Hyslop and…”
BackgroundGolabek, A. A., Soto, C., Vogel, T., & Wisniewski, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10602 · Cited by 138
Fraser, P. E., Nguyen, J. T., McLachlan, D. R., Abraham, C. R., & Kirschner, D. A. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03568.x · Cited by 139
Structure and function of amyloid in Alzheimer's disease
Morgan, C., Colombres, M., Núñez, M. T., & Inestrosa, N. C. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.10.004 · Cited by 172
Chyung, A. S. C., Greenberg, B. D., Cook, D. G., Doms, R. W., & Lee, V. M.-Y. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.671 · Cited by 114
“2 a); and (e) the detection of the same 95-kD APP fragment using a different antibody specific for APPb (i.e., 192; Seubert et al., 1992; and data not shown).”
Sastre, M., Turner, R. S., & Levy, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.35.22351 · Cited by 139
Yamazaki, T., Koo, E. H., & Selkoe, D. J. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.5.999 · Cited by 112
Self-citationMattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 129
Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Niaz, K., Jeandet, P., Clément, C., Mathew, B., Rauf, A., Rengasamy, K. R. R., Sobarzo-Sánchez, E., Ashraf, G. M., et al. (2020) · Molecules · doi:10.3390/molecules25061267 · Cited by 133
“Though Aβ1–42 is a minor species, Aβ1–40 is mainly generated under non-pathological circumstances [75,76].”
BackgroundPlasma lipidome is dysregulated in Alzheimer’s disease and is associated with disease risk genes
Liu, Y., Thalamuthu, A., Mather, K. A., Crawford, J., Ulanova, M., Wong, M. W. K., Pickford, R., Sachdev, P. S., & Braidy, N. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01362-2 · Cited by 129
Current progress in beta-amyloid immunotherapy
Schenk, D., Hagen, M., & Seubert, P. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.012 · Cited by 149
Self-citationLalowski, M., Golabek, A., Lemere, C. A., Selkoe, D. J., Wisniewski, H. M., Beavis, R. C., Frangione, B., & Wisniewski, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33623 · Cited by 137
Self-citationImmunotherapy Reduces Vascular Amyloid- in PDAPP Mice
Schroeter, S., Khan, K., Barbour, R., Doan, M., Chen, M., Guido, T., Gill, D., Basi, G., Schenk, D., Seubert, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2377-07.2008 · Cited by 133
“Preparation methods for antibodies 3D6 (recognizing A 1–5) and 266 (recognizing A 16 –23) have been described previously (Seubert et al., 1992; Johnson-Wood et al., 1997; Bard et al., 2003).”
MethodSelf-citationPathophysiology of Alzheimer's Disease
Imbimbo, B. P., Lombard, J., & Pomara, N. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.009 · Cited by 152
Zha, X., Lamba, D., Zhang, L., Lou, Y., Xu, C., Kang, D., Chen, L., Xu, Y., Zhang, L., De Simone, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01119 · Cited by 130
Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential
Wolfe, M. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004897 · Cited by 133
Olsson, A., Höglund, K., Sjögren, M. J. C., Andreasen, N., Minthon, L., Lannfelt, L., Büerger, K., Möller, H., Hampel, H. J., Davidsson, P., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00027-x · Cited by 151
CELLULAR AND MOLECULAR BIOLOGY OF ALZHEIMER'S DISEASE AND ANIMAL MODELS
Price, M. D., & Sisodia, P. D. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.435 · Cited by 132
Metadata
- Authors
- Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., & Schenk, D.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6393
- Pages
- 325-327
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2086278983
- Cited by
- 1,731
- References
- 28
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 32 · 2023: 19 · 2022: 22 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 35 · 2017: 39 · 2016: 31 · 2015: 48 · 2014: 46 · 2013: 39 · 2012: 50
- FWCI
- 72.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, cerebrospinal fluid, plasma, conditioned medium, sandwich ELISA, affinity chromatography, epitope-specific antibodies, amyloid deposition, diagnostic biomarkers
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Antibodies, Monoclonal, Brain, Cells, Cultured, Cross Reactions, Enzyme-Linked Immunosorbent Assay, Humans, Molecular Sequence Data, Peptide Fragments, Radioimmunoassay, Solubility, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.